Jeffrey Hawkins
Family · San Diego, CANPI 1679126353
Payments from drug & device makers
Across 420 payments — averaging $43.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Inari Medical, Inc.$1K
- Kestra Medical Technology Services, Inc.$1K
- Boehringer Ingelheim$991
- Novartis$979
- Novo Nordisk$877
- plus $9K from 42 others
What the payments were for
- Food & beverage$17,95799%
- Education$1161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANDEXXA$968
- FARXIGA$937
- Assure WCD$810
- FLOWTRIEVER CATHETER, S$751
- CT THROMBECTOMY SYSTEM KIT$751
- Impella$503
- BRILINTA$473
- MoMe Device$410
- Ambulatory Monitoring & Diagnostics Undivided$384
- Ozempic$382
- JARDIANCE$368
- Wegovy$248
- LOKELMA$227
- SAPIEN 3 Ultra RESILIA$207
- Acticor 7 VR-T DX$205
- CoreValve Evolut$181
- Quadra Assura CRT Defibrillator$181
- JOT DX$177
- MitraClip$164
- Barostim Neo System$145
How this compares
$18,074 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $72,309 |
| EntrestoSacubitril/Valsartan | 74 | $68,397 |
| EliquisApixaban | 28 | $42,714 |
| FarxigaDapagliflozin Propanediol | 26 | $29,965 |
| OzempicSemaglutide | 15 | $13,680 |
| Repatha SureclickEvolocumab | 14 | $10,645 |
| XareltoRivaroxaban | 11 | $9,935 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,205 |
| Ezetimibe | 69 | $3,098 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,627 |
| Rosuvastatin Calcium | 44 | $1,933 |
| Atorvastatin Calcium | 92 | $1,056 |
| Losartan Potassium | 51 | $828 |
| Metoprolol Succinate | 43 | $804 |
| Valsartan | 27 | $706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $991 | $72,30958 claims |
| NovartisEntresto | $979 | $68,39774 claims |
| PfizerEliquis | $108 | $42,71428 claims |
| AstraZenecaFarxiga | $3,749 | $29,96526 claims |
| Novo NordiskOzempic | $877 | $13,68015 claims |
| Johnson & JohnsonXarelto | $397 | $9,93511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in San Diego
- Nancy GardettoSan Diego$394K
- Dawn MeyerSan Diego$270K
- Erin DwyerSan Diego$189K
- Lizaveta NikitsinaSan Diego$36K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Jennifer KangCerritos$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.